Galapagos NV

(NASDAQ:GLPG)

Latest On Galapagos NV (GLPG):

Date/Time Type Description Signal Details
2023-05-06 09:51 ESTNewsGalapagos Stands Strong On Jyseleca Positive Clinical DataN/A
2023-05-05 21:26 ESTNewsGalapagos NV (GLPG) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 19:34 ESTNewsGalapagos GAAP EPS of €0.40, revenue of €178.9MN/A
2023-05-03 18:15 ESTNewsGalapagos Q1 2023 Earnings PreviewN/A
2023-05-03 05:16 ESTNewsGalapagos announces departure of COO and CFO Bart FiliusN/A
2023-03-30 21:01 ESTNewsGalapagos to transfer drug discovery and research activities in France to NovAliXN/A
2023-02-24 11:36 ESTNewsGalapagos NV (GLPG) Q4 2022 Earnings Call TranscriptN/A
2023-02-23 22:33 ESTNewsGalapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023N/A
2023-02-11 10:09 ESTNewsGalapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy RatingN/A
2023-02-09 18:47 ESTNewsGalapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's disease, cancels plan for EU filingN/A
2023-02-08 02:22 ESTNewsGalapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, BuyN/A
2022-12-31 07:11 ESTNewsGalapagos: Slow Transformation, But Led By An ExpertN/A
2022-11-07 11:28 ESTNewsGalapagos downgraded to market perform at Raymond James on unclear path forwardN/A
2022-11-03 19:29 ESTNewsGalapagos GAAP EPS of -€0.16, revenue of €410.2MN/A
2022-11-03 02:25 ESTNewsGalapagos Q3 2022 Earnings PreviewN/A
2022-10-10 20:03 ESTNewsGalapagos: Trading At Discount To Cash With A Fast-Growing Marketed ProductN/A
2022-10-03 19:25 ESTNewsEMA panel approves amending label for Galapagos' Jyseleca on testicular function effectsN/A
2022-09-09 14:41 ESTNewsGalapagos cut at Morgan Stanley on positive but slow transformationN/A
2022-08-06 18:23 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 20:20 ESTNewsGalapagos GAAP EPS of -€0.49, revenue of €274MN/A
2022-07-25 21:27 ESTNewsGalapagos stock dips after Jefferies slashes rating citing challenges aheadN/A
2022-06-21 19:06 ESTNewsGalapagos to enter cell therapy space with acquisition of CellPoint and AboundBioN/A
2022-05-30 23:31 ESTNewsMorgan Stanley updates biotechs with negative enterprise values & 2022 catalystsN/A
2022-05-25 07:04 ESTNewsGalapagos to license drug targets for inflammatory bowel disease from Scipher MedicineN/A
2022-05-20 09:10 ESTNewsGalapagos: Can The Company Turn Around?N/A
2022-05-06 13:39 ESTNewsGalapagos GAAP EPS of -€0.20, revenue of €136.3MN/A
2022-05-06 13:39 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 13:38 ESTNewsGalapagos NV 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-05 15:51 ESTNewsGalapagos Q1 2022 Earnings PreviewN/A
2022-03-28 07:24 ESTNewsGilead, Galapagos' Jyseleca gets approval in Japan for expanded use in ulcerative colitisN/A
2022-02-25 18:23 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-25 01:06 ESTNewsGalapagos GAAP EPS of -€1.58, revenue of €484.85MN/A
2022-02-24 05:28 ESTNewsGalapagos Q4 2021 Earnings PreviewN/A
2022-02-22 14:27 ESTNewsGalapagos: A History Of Disruptive FailuresN/A
2022-01-28 00:18 ESTNewsGalapagos at a six-month high after naming former J&J science chief as CEON/A
2022-01-27 07:39 ESTNewsGalapagos creates 1M subscription rights; stock rises 9%N/A
2022-01-26 14:26 ESTNewsEinhorn's Greenlight discloses positions in Global Payments, Capri, Galapagos, ODP Corp.N/A
2022-01-19 05:53 ESTNewsGalapagos' Jyseleca wins UK marketing authorization for ulcerative colitisN/A
2022-01-09 00:57 ESTNewsBiogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022N/A
2021-12-04 00:46 ESTNewsGalapagos announces increase in share capital with subscription right exercisesN/A
2021-12-02 09:17 ESTNewsGalapagos: The Investment Thesis Is More Appealing Than EverN/A
2021-11-15 16:53 ESTNewsGalapagos wins EU approval for Jyseleca for ulcerative colitisN/A
2021-11-08 23:33 ESTNewsGalapagos rises as analysts highlight a major catalyst aheadN/A
2021-11-05 17:29 ESTNewsGalapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 20:49 ESTNewsGalapagos reports Q3 resultsN/A
2021-11-03 23:37 ESTNewsGalapagos Q3 2021 Earnings PreviewN/A
2021-10-04 18:03 ESTNewsGalapagos posts results from post-hoc analyses of filgotinib in ulcerative colitisN/A
2021-09-22 14:07 ESTNewsGalapagos' filgotinib wins positive CHMP opinion for treatment of ulcerative colitisN/A
2021-08-19 18:51 ESTNewsGalapagos lowered to equal weight at Barclays; doubts acquisition driven upsideN/A
2021-08-08 04:48 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call TranscriptN/A

About Galapagos NV (GLPG):

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

GLPG Quotes by TradingView

See Advanced Chart

General

  • Name Galapagos NV
  • Symbol GLPG
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2005-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.glpg.com
View More

Valuation

  • Trailing PE 60.65
  • Price/Sales (Trailing 12 Mt.) 9.78
  • Price/Book (Most Recent Quarter) 1.69
  • Enterprise Value Revenue 1.18
  • Enterprise Value EBITDA 3.11
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$4.89
  • Next Year EPS Estimate -$4.50
  • Next Quarter EPS Estimate -$0.28
  • Profit Margin -58%
  • Return on Assets -2%
  • Return on Equity -11%
  • Earnings Per Share -$1.69
  • Revenue Per Share $0
  • Gross Profit 6.6 million
  • Quarterly Earnings Growth -77.6%
View More

Highlights

  • Market Capitalization 5.28 billion
  • Analyst Target Price $93.67
  • Book Value Per Share $25.49
View More

Share Statistics

  • Shares Outstanding 65.41 million
  • Shares Float 43.14 million
  • % Held by Insiders <1%
  • % Held by Institutions 11.77%
  • Shares Short 936943
  • Shares Short Prior Month 966729
  • Short Ratio 2.3
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 0.28
  • 52 Week High $233.14
  • 52 Week Low $79.59
  • 50 Day Moving Average 90.41
  • 200 Day Moving Average 114.01
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Galapagos NV (GLPG) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Galapagos NV (GLPG) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-18-$1.06-$1.5330.28%
2020-09-302020-11-05$131.82 million-$1.49-$0.99-51.08%
2020-06-302020-08-06$N/A-$2.10-$0.85-147.49%
2020-03-312020-05-07$N/A-$0.85-$0.862.01%
2019-12-312020-02-20$160.81 million-$2.34-$0.79-193.91%
2019-09-302019-10-24$701.86 million$7.05$3.29114.55%
2019-06-302019-07-25$76.28 million-$0.97-$1.2522.41%
2019-03-312019-04-25$45.88 million-$0.99-$1.022.59%
2018-12-312019-02-21$129.35 million$0.31-$0.90134.1%
2018-09-302018-10-24$119.48 million$0.32-$1.10129.08%
2018-06-302018-08-02$66.38 million-$0.49-$1.0051.42%
2018-03-312018-04-25$55.24 million-$0.89-$1.1119.74%
2017-12-312018-02-22$61.81 million-$0.73-$0.9120.04%
2017-09-302017-10-26$42.3 million-$0.84-$0.9310.37%
2017-06-302017-07-27$40.69 million-$0.86-$0.67-29.5%
2017-03-312017-04-27$42.65 million-$0.32-$0.5946.03%
2016-12-312017-02-23$86.89 million$1.05$0.10897.14%
2016-09-302016-10-27$19.3 million-$0.57-$0.6614.05%
2016-06-302016-07-28$36.92 million-$0.11-$0.2146.22%
2016-03-312016-04-28$16.88 million$0.89$1.30-31.2%
2015-12-312016-03-03$13.08 million-$1.69-$0.84-101.49%
2015-09-302015-11-13$11.52 million-$0.72$4.06-117.73%
2015-06-302015-08-06$19.68 million-$0.59-$0.35-68.57%

Galapagos NV (GLPG) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Galapagos NV (GLPG) Chart:

Galapagos NV (GLPG) News:

Below you will find a list of latest news for Galapagos NV (GLPG) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Galapagos NV (GLPG) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-1917.50CALL0 0169.53TRUE00
2025-09-192012.6CALL0 20137.64TRUE00
2025-09-1922.50CALL0 0109.25TRUE00
2025-09-19250CALL0 083.37TRUE00
2025-09-1927.50CALL0 059.11TRUE00
2025-09-19301.2CALL0 3726.81TRUE00
2025-09-1932.52.65CALL0 1078.96FALSE00
2025-09-19351.73CALL0 1109.97FALSE00
2025-09-1937.50.35CALL0 23134.48FALSE00
2025-09-19402.56CALL0 1101.11FALSE00
2025-09-1942.50CALL0 0173.38FALSE00
2025-09-19452.45CALL0 1189.59FALSE00
2025-09-1947.50CALL0 0204.26FALSE00
2025-09-1917.50PUT0 0339.02FALSE00
2025-09-19200PUT0 0285.85FALSE00
2025-09-1922.50PUT0 0239.04FALSE00
2025-09-19250PUT0 0196.62FALSE00
2025-09-1927.50.5PUT0 1457.83FALSE00
2025-09-19301.95PUT0 1120.28FALSE00
2025-09-1932.53.04PUT0 678.6TRUE00
2025-09-19353PUT0 231.22TRUE00
2025-09-1937.50PUT0 0134.34TRUE00
2025-09-194010.2PUT0 20155.22TRUE00
2025-09-1942.50PUT0 0173.52TRUE00
2025-09-19450PUT0 0189.87TRUE00
2025-09-1947.50PUT0 0204.69TRUE00
2025-10-1712.50CALL0 0154.29TRUE00
2025-10-17150CALL0 0118.98TRUE00
2025-10-1717.50CALL0 095.9TRUE00
2025-10-17200CALL0 086.2TRUE00
2025-10-1722.50CALL0 063.45TRUE00
2025-10-17257.5CALL0 8536.91TRUE00
2025-10-1727.56.2CALL0 223.24TRUE00
2025-10-17304.7CALL0 63530.17TRUE00
2025-10-1732.51.9CALL0 5823.98FALSE00
2025-10-17350.65CALL0 7472.07FALSE00
2025-10-1737.50.9CALL0 488.42FALSE00
2025-10-17400.65CALL0 8102.25FALSE00
2025-10-1742.50CALL0 0114.34FALSE00
2025-10-17450CALL0 0125.12FALSE00
2025-10-1747.50CALL0 0134.87FALSE00
2025-10-17500CALL0 0143.79FALSE00
2025-10-1712.50PUT0 0317.91FALSE00
2025-10-17150PUT0 0267.14FALSE00
2025-10-1717.50PUT0 0225.71FALSE00
2025-10-17200PUT0 2190.43FALSE00
2025-10-1722.50PUT0 1159.39FALSE00
2025-10-17250PUT0 41131.26FALSE00
2025-10-1727.51.1PUT0 62105.01FALSE00
2025-10-17301.96PUT0 30432.64FALSE00
2025-10-1732.51.29PUT0 19731.16TRUE00
2025-10-17350PUT0 028.41TRUE00
2025-10-1737.50PUT0 029.9TRUE00
2025-10-17400PUT0 0104.82TRUE00
2025-10-1742.50PUT0 0117.16TRUE00
2025-10-17450PUT0 0128.21TRUE00
2025-10-1747.50PUT0 0138.23TRUE00
2025-10-17500PUT0 069.31TRUE00
2026-01-1612.50CALL0 085.02TRUE00
2026-01-16150CALL0 058.69TRUE00
2026-01-1617.50CALL0 0131.25TRUE00
2026-01-16200CALL0 054.41TRUE00
2026-01-1622.50CALL0 051.04TRUE00
2026-01-16250CALL0 032.69TRUE00
2026-01-1627.50CALL0 027.78TRUE00
2026-01-16302.95CALL0 1636.76TRUE00
2026-01-1632.52.9CALL0 4637.65FALSE00
2026-01-16351.75CALL0 11226.75FALSE00
2026-01-1637.50.75CALL0 151.89FALSE00
2026-01-16400.85CALL0 759.6FALSE00
2026-01-1642.50CALL0 066.87FALSE00
2026-01-16450CALL0 073.35FALSE00
2026-01-1647.50CALL0 079.21FALSE00
2026-01-16500CALL0 084.55FALSE00
2026-01-1612.50PUT0 0190.9FALSE00
2026-01-16150PUT0 0160.6FALSE00
2026-01-1617.50PUT0 0135.89FALSE00
2026-01-16200PUT0 0114.86FALSE00
2026-01-1622.50PUT0 070.85FALSE00
2026-01-16250PUT0 070.95FALSE00
2026-01-1627.50PUT0 064.07FALSE00
2026-01-16301.58PUT0 1053.14FALSE00
2026-01-1632.50PUT0 042.99TRUE00
2026-01-16350PUT0 028.21TRUE00
2026-01-1637.50PUT0 027.04TRUE00
2026-01-16400PUT0 025.28TRUE00
2026-01-1642.50PUT0 030.68TRUE00
2026-01-16450PUT0 035.61TRUE00
2026-01-1647.50PUT0 086.3TRUE00
2026-01-16500PUT0 092.05TRUE00
2026-04-1717.50CALL0 057.67TRUE00
2026-04-17200CALL0 039.6TRUE00
2026-04-1722.50CALL0 031.2TRUE00
2026-04-17250CALL0 034.6TRUE00
2026-04-1727.50CALL0 029.04TRUE00
2026-04-17300CALL0 028.98TRUE00
2026-04-1732.50CALL0 026.18FALSE00
2026-04-17350CALL0 031.56FALSE00
2026-04-1737.50CALL0 039.46FALSE00
2026-04-17400CALL0 045.55FALSE00
2026-04-1742.50CALL0 051.28FALSE00
2026-04-17450CALL0 056.37FALSE00
2026-04-1747.50CALL0 060.97FALSE00
2026-04-1717.50PUT0 0106.96FALSE00
2026-04-17200PUT0 090.55FALSE00
2026-04-1722.50PUT0 056.07FALSE00
2026-04-17250PUT0 063.11FALSE00
2026-04-1727.50.85PUT0 038.24FALSE00
2026-04-17300PUT0 040.38FALSE00
2026-04-1732.50PUT0 031.28TRUE00
2026-04-17350PUT0 026.52TRUE00
2026-04-1737.50PUT0 026.21TRUE00
2026-04-17400PUT0 022.06TRUE00
2026-04-1742.50PUT0 026.62TRUE00
2026-04-17450PUT0 030.79TRUE00
2026-04-1747.50PUT0 034.64TRUE00

Latest GLPG Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$54.06
Jun 13, 2022 7:58 PM EST10$53.98
Jun 13, 2022 7:58 PM EST1$53.98
Jun 13, 2022 7:59 PM EST1$53.985
Jun 13, 2022 7:59 PM EST100$53.99

Galapagos NV (GLPG) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000090221920000071/0000902219-20-000071-index.htm
2019-07-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465919040709/0001104659-19-040709-index.htm
2019-07-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919041473/0001104659-19-041473-index.htm
2019-08-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919047927/0001104659-19-047927-index.htm
2019-11-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919059005/0001104659-19-059005-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465920021860/0001104659-20-021860-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000114036120003311/0001140361-20-003311-index.htm
2019-05-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003728/0001171843-19-003728-index.htm
2019-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003920/0001171843-19-003920-index.htm
2019-06-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004030/0001171843-19-004030-index.htm
2019-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004093/0001171843-19-004093-index.htm
2019-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004317/0001171843-19-004317-index.htm
2019-07-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004585/0001171843-19-004585-index.htm
2019-07-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004659/0001171843-19-004659-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005832/0001171843-19-005832-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005833/0001171843-19-005833-index.htm
2019-09-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006023/0001171843-19-006023-index.htm
2019-09-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006051/0001171843-19-006051-index.htm
2019-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006114/0001171843-19-006114-index.htm
2019-10-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006401/0001171843-19-006401-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006466/0001171843-19-006466-index.htm
2019-10-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006850/0001171843-19-006850-index.htm
2019-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006892/0001171843-19-006892-index.htm
2019-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007092/0001171843-19-007092-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007260/0001171843-19-007260-index.htm
2019-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007410/0001171843-19-007410-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007516/0001171843-19-007516-index.htm
2019-11-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007642/0001171843-19-007642-index.htm
2019-11-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007826/0001171843-19-007826-index.htm
2019-12-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008012/0001171843-19-008012-index.htm
2019-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008255/0001171843-19-008255-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000139/0001171843-20-000139-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000140/0001171843-20-000140-index.htm
2020-01-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000174/0001171843-20-000174-index.htm
2020-01-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000237/0001171843-20-000237-index.htm
2020-01-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000469/0001171843-20-000469-index.htm
2020-01-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000556/0001171843-20-000556-index.htm
2020-03-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320001794/0001171843-20-001794-index.htm
2020-04-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002640/0001171843-20-002640-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002674/0001171843-20-002674-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002689/0001171843-20-002689-index.htm
2020-05-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320003977/0001171843-20-003977-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004053/0001171843-20-004053-index.htm
2020-06-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004164/0001171843-20-004164-index.htm
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-07-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005194/0001171843-20-005194-index.htm
2020-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005906/0001171843-20-005906-index.htm
2020-08-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005998/0001171843-20-005998-index.htm
2020-08-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006087/0001171843-20-006087-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006405/0001171843-20-006405-index.htm
2020-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006525/0001171843-20-006525-index.htm
2020-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006651/0001171843-20-006651-index.htm
2020-09-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006681/0001171843-20-006681-index.htm
2020-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006727/0001171843-20-006727-index.htm
2020-10-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007002/0001171843-20-007002-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007061/0001171843-20-007061-index.htm
2020-10-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007261/0001171843-20-007261-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007481/0001171843-20-007481-index.htm
2020-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007726/0001171843-20-007726-index.htm
2019-08-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519234109/0001193125-19-234109-index.htm
2019-09-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519250691/0001193125-19-250691-index.htm
2019-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519272244/0001193125-19-272244-index.htm
2019-10-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519274853/0001193125-19-274853-index.htm
2020-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520088879/0001193125-20-088879-index.htm
2020-04-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520126328/0001193125-20-126328-index.htm
2020-05-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520139028/0001193125-20-139028-index.htm
2020-10-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1421876/000119312520267249/0001193125-20-267249-index.htm
2019-07-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837019006344/0001558370-19-006344-index.htm
2020-03-2720-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1421876/000155837020003270/0001558370-20-003270-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837020009632/0001558370-20-009632-index.htm